Deborah Ann Miller Sells 2,589 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 2,589 shares of Nuvalent stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total value of $251,547.24. Following the completion of the sale, the insider owned 42,134 shares of the company’s stock, valued at $4,093,739.44. This trade represents a 5.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Deborah Ann Miller also recently made the following trade(s):

• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total transaction of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The stock was sold at an average price of $103.16, for a total transaction of $2,248,888.00.
• On Monday, October 20th, Deborah Ann Miller sold 5,000 shares of Nuvalent stock. The shares were sold at an average price of $94.91, for a total transaction of $474,550.00.
• On Thursday, October 16th, Deborah Ann Miller sold 12,376 shares of Nuvalent stock. The shares were sold at an average price of $91.66, for a total transaction of $1,134,384.16.
• On Wednesday, October 15th, Deborah Ann Miller sold 15,624 shares of Nuvalent stock. The stock was sold at an average price of $89.98, for a total value of $1,405,847.52.

Nuvalent Trading Down 3.9%

NUVL stock opened at $102.67 on Friday. The stock has a 50-day moving average price of $102.73 and a two-hundred day moving average price of $89.01. The company has a market cap of $7.47 billion, a PE ratio of -19.30 and a beta of 1.32. Nuvalent, Inc. has a 12-month low of $55.53 and a 12-month high of $112.88.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period last year, the firm posted ($1.28) earnings per share. Equities analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NUVL has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a report on Wednesday, October 8th. Truist Financial set a $140.00 price objective on Nuvalent in a research note on Monday, November 24th. Leerink Partners upped their target price on Nuvalent from $140.00 to $149.00 and gave the stock an “outperform” rating in a research report on Monday, November 17th. The Goldman Sachs Group raised their target price on Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Robert W. Baird boosted their price target on Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Fifteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $138.33.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: Analysts remain constructive — several firms have recently initiated/raised coverage and price targets (Cantor Fitzgerald, Leerink, Baird, Goldman Sachs, Truist among others), leaving a consensus target near $138 that supports longer-term upside. MarketBeat Nuvalent Coverage
• Neutral Sentiment: Company fundamentals reminder — Nuvalent is clinical-stage (lead assets NVL‑520, NVL‑655) and reported an EPS miss on Oct. 30 (($1.70) vs. ($1.39) expected); pipeline readouts and clinical data remain the key medium-term catalysts/risks. Earnings / Profile
• Neutral Sentiment: Institutional ownership is very high (~97%), and some small funds added modest positions recently — this reduces free-float liquidity but can amplify moves when insiders trade. Institutional Activity
• Negative Sentiment: Concentrated insider selling: CEO James R. Porter sold large blocks (17,890 shares on Jan. 5 and 9,543 shares on Jan. 6 at ~ $97 / share), a material reduction in his position that likely weighs on sentiment. SEC Filing – CEO Sales
• Negative Sentiment: CFO Alexandra Balcom and other insiders (director Christopher D. Turner, Deborah A. Miller, Henry E. Pelish) also sold multiple tranches on Jan. 5–6 (several thousand shares each), collectively trimming insider stakes and adding selling pressure. SEC Filing – CFO Sales SEC Filing – Turner SEC Filing – Miller SEC Filing – Pelish

Hedge Funds Weigh In On Nuvalent

Hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new stake in Nuvalent during the third quarter valued at approximately $107,794,000. Wellington Management Group LLP increased its holdings in shares of Nuvalent by 46.0% in the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after acquiring an additional 724,491 shares during the last quarter. Norges Bank bought a new stake in shares of Nuvalent in the 2nd quarter valued at approximately $28,582,000. Braidwell LP raised its position in shares of Nuvalent by 39.8% during the 2nd quarter. Braidwell LP now owns 1,175,876 shares of the company’s stock valued at $89,719,000 after acquiring an additional 334,931 shares in the last quarter. Finally, Polar Capital Holdings Plc lifted its stake in Nuvalent by 25.3% during the third quarter. Polar Capital Holdings Plc now owns 1,022,225 shares of the company’s stock worth $88,402,000 after purchasing an additional 206,138 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.